Lundbeck Ready To File Alzheimer’s Agitation Treatment, A Potential First
Filing Expected In Q4
Brexpiprazole could be approved as soon as 2023, and Lundbeck has pledged to support its uptake with investment in its salesforce and direct-to-consumer advertising.
